MIN-101

MIN-101 (also known as Roluperidone) is a novel drug that is currently under investigation for its potential use in the treatment of schizophrenia. It is being developed by Minerva Neurosciences and is currently in Phase III clinical trials.

Mechanism of Action

MIN-101 is a novel compound that acts as a sigma-2 receptor antagonist and a 5-HT2A receptor antagonist. The sigma-2 receptor is thought to be involved in the regulation of neuronal remodeling and survival, while the 5-HT2A receptor is involved in various psychiatric disorders, including schizophrenia.

Clinical Trials

MIN-101 has undergone several clinical trials to assess its safety and efficacy in the treatment of schizophrenia. In a Phase IIb clinical trial, the drug was found to significantly improve negative symptoms and cognitive impairment associated with schizophrenia, without causing the side effects commonly associated with other antipsychotic medications.

Potential Benefits

One of the potential benefits of MIN-101 is that it does not block dopamine receptors, which are the target of most current antipsychotic medications. This means that it may not cause the extrapyramidal symptoms (such as tremors and rigidity) that are often associated with these drugs. In addition, it may also have a beneficial effect on the cognitive impairment that is often seen in patients with schizophrenia.

See Also

• Schizophrenia
• Antipsychotic
• Clinical trial
• 5-HT2A receptor
• Sigma-2 receptor

References

MIN-101 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia